The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

20 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Progress in discovery of small-molecule modulators of protein-protein interactions via fragment screening.EBI
Pfizer
Bisphenol A binds to Ras proteins and competes with guanine nucleotide exchange: implications for GTPase-selective antagonists.EBI
Ruhr University Of Bochum
Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.EBI
The University Of Arizona
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.EBI
Universite£
Chalcones bearing a 3,4,5-trimethoxyphenyl motif are capable of selectively inhibiting oncogenic K-Ras signaling.EBI
Wright State University
Identification of the Clinical Development Candidate EBI
Array Biopharma
Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRASEBI
Astrazeneca
Inhibitors of G12C Mutant Ras Proteins for the Treatment of Cancers.EBI
Usona Institute
Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRASEBI
China Pharmaceutical University
Inhibitors of KRAS May Potentially Provide Effective Cancer Treatment.EBI
Therachem Research Medilab
Discovery of EBI
Amgen
Discovery of a Covalent Inhibitor of KRASEBI
TBA
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity.EBI
Array Biopharma
Discovery of covalent enzyme inhibitors using virtual docking of covalent fragments.EBI
University Of Houston
Covalent Guanosine Mimetic Inhibitors of G12C KRAS.EBI
Dana Farber Cancer Institute
New Frontiers in Druggability.EBI
Stony Brook University
Inhibition of Ras-Effector Interaction by Cyclic Peptides.EBI
The Ohio State University
Precedence and Promise of Covalent Inhibitors of EGFR and KRAS for Patients with Non-Small-Cell Lung Cancer.EBI
Pfizer
Crystal Structure of a Human K-Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d.EBI
Takeda Pharmaceutical
Investigation of the structural requirements of K-Ras(G12D) selective inhibitory peptide KRpep-2d using alanine scans and cysteine bridging.EBI
Takeda Pharmaceutical